Evidence map›Paper›PMID 37313052›Full record

ArticleBioinformation2022

Persistence of hepatitis B surface antibody to hepatitis B vaccine among medical college students in Najran University, Saudi Arabia.

Alshehri Ahmad A, Alshamrani Saleh A, Elnoubi Osman A, Alshahrani Abdullah J, Saif Ahmad M, Nahari Mohammed H, Elfaki Nahid K, Alshahrani Mohammed A, Alfateh Saeed M, Mashraqi Mutaib M

Abstract read
In one paragraph

Article in Bioinformation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Epidemiologic and clinical updates on viral infections in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alshehri Ahmad ADepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Alshamrani Saleh ADepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Elnoubi Osman ADepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Alshahrani Abdullah JDepartment of Public Health, General Directorate of Health Affairs in Asir Region, Abha, Saudi Arabia.
Saif Ahmad MDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Nahari Mohammed HDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Elfaki Nahid KDepartment of Community Health Nursing, College of Nursing, Najran University, P.O. Box 1988, Najran, Saudi Arabia.
Alshahrani Mohammed ADepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Alfateh Saeed MDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.
Mashraqi Mutaib MDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Around 257 to 291 million people worldwide are infected with the hepatitis B virus (HBV). Immunization is one of the most effective ways to combat HBV infection. Saudi Arabia implemented a mandatory hepatitis B immunization program in 1989. This project investigated the levels of hepatitis B surface antibodies (anti-HBs) among medical students in the college of applied medical science at Najran University in December 2020. Students (n=82) were tested for anti-HBs levels using a chemiluminescent microparticle immunoassay (CMIA). Anti-HBs levels were the main outcome measures. Results showed that about 81.7% of participants had an insufficient amount of Anti-HBs levels (<10 IU/ L) compared to 18.3 % of participants who had protective levels of anti-HBs (≥10 IU/ L). However, 78.5% of the reactive group was at risk of losing immunity with a level between 12 and 42 IU/ L. Our study also showed an association between the age and the level of anti-HBs. Moreover, male students were at more risk than female students. Our results showed a strong relationship between Blood Groups and Anti-HBs antibody levels. The O+ (with 38.8%) and A+ (with 25.4%) blood groups showed the highest percentage amongst participants who had inadequate protection of anti-HBs (<10 IU/ L). Thus, data helps in our understanding and observations on anti-HBV immunity in individuals twenty years after being vaccinated as a child. According to the findings of our study, a large majority of students had a non-protective anti-HBs titer.

Indexed as

ABO/Rh blood groupsChemiluminescence assayHepatitis B virus

Identifiers

PMID37313052
PMCPMC10259232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.